1. Home
  2. FA vs RARE Comparison

FA vs RARE Comparison

Compare FA & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FA
  • RARE
  • Stock Information
  • Founded
  • FA 2003
  • RARE 2010
  • Country
  • FA United States
  • RARE United States
  • Employees
  • FA N/A
  • RARE N/A
  • Industry
  • FA Business Services
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • FA Consumer Discretionary
  • RARE Health Care
  • Exchange
  • FA Nasdaq
  • RARE Nasdaq
  • Market Cap
  • FA 2.8B
  • RARE 2.6B
  • IPO Year
  • FA 2021
  • RARE 2014
  • Fundamental
  • Price
  • FA $15.76
  • RARE $31.21
  • Analyst Decision
  • FA Hold
  • RARE Strong Buy
  • Analyst Count
  • FA 5
  • RARE 14
  • Target Price
  • FA $20.67
  • RARE $86.64
  • AVG Volume (30 Days)
  • FA 871.8K
  • RARE 1.8M
  • Earning Date
  • FA 11-11-2025
  • RARE 11-04-2025
  • Dividend Yield
  • FA N/A
  • RARE N/A
  • EPS Growth
  • FA N/A
  • RARE N/A
  • EPS
  • FA N/A
  • RARE N/A
  • Revenue
  • FA $1,251,464,000.00
  • RARE $610,159,000.00
  • Revenue This Year
  • FA $84.14
  • RARE $19.72
  • Revenue Next Year
  • FA $5.93
  • RARE $23.29
  • P/E Ratio
  • FA N/A
  • RARE N/A
  • Revenue Growth
  • FA 65.34
  • RARE 26.77
  • 52 Week Low
  • FA $12.32
  • RARE $25.81
  • 52 Week High
  • FA $20.79
  • RARE $58.00
  • Technical
  • Relative Strength Index (RSI)
  • FA 51.32
  • RARE 57.90
  • Support Level
  • FA $14.89
  • RARE $29.60
  • Resistance Level
  • FA $15.50
  • RARE $31.15
  • Average True Range (ATR)
  • FA 0.61
  • RARE 1.19
  • MACD
  • FA 0.08
  • RARE 0.22
  • Stochastic Oscillator
  • FA 73.60
  • RARE 89.42

About FA First Advantage Corporation

First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: